ArticleIndian journal of nephrology
Colistin Nephrotoxicity-Age and Baseline kidney Functions Hold the Key.
Article in Indian journal of nephrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06650384 (Evaluation of the Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid on the Occurrence and Severity of Colistin-Induced Nephrotoxicity in Critically Ill Patients), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid on the Occurrence and Severity of Colistin-Induced Nephrotoxicity in Critically Ill Patients
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Factors affecting the effectiveness and safety of colistin in treating drug-resistant gram-negative bacterial infections: a meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Evaluating the effects of intravenous magnesium sulfate for prevention of colistin induced acute kidney injury: an open-label, placebo-controlled, block randomized clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2025Trial
- Article
- Does a Loading Dose Improve Outcomes? Colistin Therapy for Urinary Tract Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2026Article
- mcr gene family evolution and structural mechanisms of colistin resistance: from mcr-1 to emerging variants.Archives of microbiology · 2026Review
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin.PLoS pathogens · 2024Article
- Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.Clinical and translational science · 2024Article
- Evaluation of Serum Creatinine Levels with Reference Change Value in Patients Receiving Colistin Treatment.Laboratory medicine · 2023Article
- Overview of Antibiotic-Induced Nephrotoxicity.Kidney international reports · 2023Review
- Nephrotoxicity caused by colistin use in ICU: a single centre experience.BMC nephrology · 2023Observational
- The Prevalence and Risk Factors of Acute Kidney Injury during Colistin Therapy: A Retrospective Cohort Study from Lebanon.Antibiotics (Basel, Switzerland) · 2023Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith the emergence of multidrug-resistant gram-negative bacterial infections, there has been a surge in the use of Colistin in recent times. The most important side effect of Colistin use is its nephrotoxicity. The study was designed to assess the effect on kidney function and the risk factors for nephrotoxicity in patients treated with Colistin.
methodsThe study is a retrospective one, which included patients who received Colistin for more than 48 hours. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) four-variable equation and acute kidney injury (AKI) was diagnosed as per the Kidney Disease Improving Global Outcome (KDIGO) criteria.
resultsOf the 150 patients studied, 59 patients (39.2%) developed AKI within a median period of 4 days (Range 2-20 days) of initiation of Colistin. Age, eGFR at the start of therapy and requirement of vasopressor support for treatment of septic shock were the most important risk factors associated with nephrotoxicity. Among patients with AKI, nearly half had only mild worsening of renal functions to KDIGO AKI stage 1. Nearly 75% of patients with AKI had complete or partial recovery of renal functions after stopping Colistin.
conclusionColistin has significant nephrotoxicity, the risk being higher with older age and baseline renal dysfunction. It is important to monitor renal functions early and at regular intervals after initiating therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.